DL
Therapeutic Areas
Basilea Pharmaceutica Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Cresemba (isavuconazole) | Invasive aspergillosis & mucormycosis | Marketed |
| Zevtera/Mabelio (ceftobiprole) | Community-acquired bacterial pneumonia (CABP), Staphylococcus aureus bacteremia (SAB) | Marketed |
| Ceftobiprole (Pediatric) | Pediatric complicated skin and skin structure infections (cSSTI) | Phase 3 |
| Ceftibuten-ledaborbactam (C/L) | Complicated urinary tract infections (cUTI) caused by multidrug-resistant pathogens | Phase 3 |
| BAL2420 | Multidrug-resistant Gram-negative infections | Phase 1 |
| BAL38072 | Invasive fungal infections | Preclinical |
Leadership Team at Basilea Pharmaceutica
DV
David Veitch
Chief Executive Officer
DA
Dr. Achim Kaufhold
Chief Medical Officer
RS
Ronald Scott
Chief Financial Officer